BioSpace News Archive

CareDx, Inc. today announced the enrollment of the first patient in the multicenter, observational, prospective ALAMO registry to improve lung transplant patient care.

Applied Therapeutics, Inc. today announced the initiation of a registrational phase 2/3 study of AT-007 in Sorbitol Dehydrogenase (SORD) Deficiency.

Senhwa Biosciences, Inc. announced that an abstract highlighting preliminary clinical data for their lead drug candidate, Silmitasertib (CX-4945) has been accepted for e-poster with an oral presentation at the upcoming 2022 American Academy of Dermatology (AAD) annual meeting in Boston, Massachusetts, held from March 25-29, 2022.

atai Impact’s first major initiative will support promising academics in researching the therapeutic potential of psychedelic compounds to address unmet needs in mental health.

Seres Therapeutics, Inc. today announced preliminary microbiome data analyses from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC).

Nodexus Inc. has raised an oversubscribed $30M Series A financing that will allow the company to expand manufacturing of its flagship NX One platform as well as build its commercialization capabilities and pipeline to meet surging demand.

Xeris Biopharma Holdings, Inc. today announced that its commercialization partner, Tetris Pharma (Tetris), has launched Ogluo® (glucagon injection) in the United Kingdom and it is now available by prescription for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

Singular Genomics Systems, Inc. today announced the commercial launch of the G4, the world’s most powerful benchtop sequencer.

Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced the appointment of Mas Matsuda, Esq. as General Counsel and Corporate Secretary.

Corcept Therapeutics Incorporated today announced the preliminary results of its previously announced tender offer to purchase up to 10,000,000 shares of its common stock, par value $0.001 per share.